CorestemChemon's Neuronata-R Shows Significant Benefits in ALS Slow Progressors in Phase 3 Trial
Key Insights
CorestemChemon's Phase 3 ALSummit trial of Neuronata-R demonstrated statistically significant improvements in ALS (search) patients classified as slow progressors, with meaningful gains in functional rating scales and respiratory capacity.
Biomarker analysis revealed sustained reductions in neurofilament light chain (search) and MCP-1 (search), indicating neuroprotective effects that support a precision-medicine approach for ALS (search) treatment.
The company plans to pursue FDA accelerated approval pathway discussions in Q4 2025, with a Biologics License Application submission targeted for 2026 based on the subgroup efficacy data.
CorestemChemon Inc. (search) has reported promising Phase 3 clinical trial results for Neuronata-R®, an autologous mesenchymal stem cell therapy for amyotrophic lateral sclerosis (search) (ALS (search)), demonstrating significant benefits in a specific patient subgroup. The findings, presented at the PACTALS 2025 conference in Melbourne, Australia, show meaningful improvements in patients classified as "slow progressors" and support a biomarker-driven precision medicine approach.
Subgroup Analysis Reveals Statistically Significant Benefits
While the overall Phase 3 ALSummit trial did not meet its primary and secondary endpoints, Neuronata-R® demonstrated meaningful efficacy in patients with slower disease progression. At 12 months, participants in the slow-progressor subgroup receiving Neuronata-R® achieved statistically significant improvements across multiple measures compared to placebo.
The ALSFRS-R functional rating scale showed scores of 31.2 versus 26.4 in the placebo group (p=0.001). The Combined Assessment of Function and Survival (CAFS) demonstrated values of 20.95 and 24.78 versus 17.92 in placebo (p=0.024; p=0.041). Additionally, slow vital capacity, a measure of respiratory function, reached 62.2% versus 50.6% in placebo (p=0.017, Study Group 2).
Professor Ki-Uk Oh from the Department of Neurology at Hanyang University Hospital (search)'s Advanced Regenerative Medicine Center, who served as principal investigator of the ALSummit trial, formally presented the complete Phase 3 results during the conference.
Biomarker Data Support Neuroprotective Mechanism
Biomarker analysis revealed sustained reductions in neurofilament light chain (search) (NfL (search)) and MCP-1 (search), indicating a strong link between neuroprotection and clinical outcomes. These findings strengthen the case for biomarker-guided patient stratification and support a precision-medicine strategy in ALS (search) drug development, reflecting the evolving global regulatory landscape.
The biomarker reductions provide additional validation of Neuronata-R®'s targeted mechanism of action and may play a crucial role in regulatory discussions regarding accelerated approval pathways.
Regulatory Strategy and Timeline
CorestemChemon stated that the PACTALS 2025 results represent an important step for regulatory discussions. The company plans to request a Type-C meeting with the U.S. Food and Drug Administration (search) (FDA) in Q4 2025 to discuss the dataset and biomarker-driven subgroup efficacy.
Based on these discussions, CorestemChemon plans to submit a Biologics License Application (BLA) within 2026, aiming to pursue an accelerated approval pathway aligned with precedents in ALS (search), including the FDA's decision on Tofersen.
Innovative Therapeutic Approach
Neuronata-R® uniquely addresses the complex mechanisms of ALS (search) by leveraging mesenchymal stem cells derived from the patient's own bone marrow. These cells exert anti-inflammatory and immunomodulatory effects, protect motor neurons (search), and through paracrine signaling, secrete trophic factors, cytokines, and extracellular vesicles that modulate the microenvironment and reduce neuroinflammation. By targeting these underlying pathological processes, Neuronata-R® is designed to interrupt the neurodegenerative cascade.
Clinical Development History
Neuronata-R® (Lenzumestrocel), developed and commercialized by CorestemChemon Inc. (search), represents over two decades of research, with the company beginning ALS (search) research in 2002. The therapy obtained approval from Korea's Ministry of Food and Drug Safety (search) (MFDS (search)) in 2014 and has been administered to more than 400 commercial patients and 190 clinical trial participants with no treatment-related serious adverse events reported.
The therapy holds Orphan Drug Designation from both the U.S. FDA (2018) and the European Medicines Agency (search) (2019). CorestemChemon completed a Phase 2 trial in 2014 and its Phase 3 trial in 2024, with the final Clinical Study Report submitted to the MFDS (search).